Study of M1 virus injection for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a virus called M1 (VRT106) that may be able to infect and destroy cancer cells. It's given by injection directly into a tumor, and is for people whose advanced solid tumors haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that is advanced or has spread, and standard treatments either didn't work or caused too many side effects.
- You are between 18 and 75 years old.
- You have at least one tumor that can be injected with the study virus.
- You are able to take care of yourself (ECOG score 0-1).
- You have not been treated with an oncolytic virus or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called M1-c6v1 given through an IV for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective.
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
This early-stage trial tests a new injection called CMTS1215 in people with solid tumors (cancers that form in organs or tissues) who have tried standard treatments without success. The goal is to see if CMTS1215 can help when other options haven't worked.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.